The Benchmark Company initiated coverage on Kamada with a new price target
$KMDA
Biotechnology: Pharmaceutical Preparations
Health Care
The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $15.00 | Buy | The Benchmark Company |
| 7/3/2024 | $18.00 | Buy | Stifel |
Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm
REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in
Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm
REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in
REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h
The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00
Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)